Bicyclic Compound Selective FP Receptor Agonist for Glaucoma
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current glaucoma treatments lack strong and sustained intraocular pressure lowering action with minimal side effects, as existing prostaglandin derivatives often cause eye stimulation and protein increase in aqueous humor.
Innovation Solution
A compound with selective agonistic activity on the FP receptor, exhibiting low agonistic activity on IP and EP1 receptors, represented by a specific chemical formula, which effectively lowers intraocular pressure without causing ocular side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stress or pressure
If existing prostaglandin derivatives are used to lower intraocular pressure, then intraocular pressure reduction is achieved, but ocular side effects such as hyperemia and aqueous humor protein increase occur
Solution Approach 1:
The patent applies local quality by designing a compound with specific structural features (bicyclic skeleton with particular substituent patterns) that confer selective agonistic activity on the FP receptor while minimizing activity on IP and EP1 receptors. This localized molecular design ensures the drug acts specifically on target tissues (ciliary body for aqueous humor production) without affecting other ocular structures, thereby achieving intraocular pressure reduction without ocular side effects
Solution Approach 2:
The patent employs parameter changes by modifying the chemical structure of prostaglandin derivatives to alter receptor selectivity. Specifically, the compound of formula (I) with its defined substituents (W1, W2, W3, R1-R10) changes the pharmacological parameters to achieve strong FP receptor agonism while maintaining low IP and EP1 receptor activity, thus resolving the contradiction between efficacy and side effects
2Reliability
If administration frequency or concentration is increased to achieve stronger intraocular pressure lowering action, then pressure reduction efficacy is improved, but side effects become more prominent
Solution Approach 1:
The patent achieves sustained pressure reduction without increased dosing by changing the pharmacological parameters of the compound. The bicyclic structure with specific substituents provides high FP receptor selectivity and sustained agonistic activity, allowing for once-daily administration with prolonged efficacy. This structural parameter change eliminates the need for frequent dosing while maintaining reliable pressure control and avoiding side effects
3Reliability
If joint use of drugs with different mechanisms of action is performed to seek stronger intraocular pressure lowering action, then pressure reduction is enhanced, but complexity of treatment increases
Solution Approach 1:
The patent applies universality by designing a single compound that performs multiple therapeutic functions: it acts as a selective FP receptor agonist to reduce intraocular pressure, provides sustained efficacy for once-daily dosing, and avoids ocular side effects through high receptor selectivity. This multi-functional molecule replaces the need for combination therapy with multiple drugs having different mechanisms of action, simplifying the treatment regimen while maintaining enhanced efficacy
Data Source
Figure 1~2
AI summary
Provided is a compound which has strong and sustaining intraocular pressure lowering action and, further, has no fear of side effect on eyes. Since a compound represented by the formula (I): wherein definition of each group is as described in the specification, or a salt thereof, a solvate thereof, or a prodrug thereof has strong and sustaining intraocular pressure lowering action and, further, has no side effect on eyes such as ocular stimulating property (hyperemia, corneal clouding etc.), aqueous humor protein rise etc., it has high safety, and can be an excellent agent for preventing and/or treating glaucoma etc.